Table 3.
Cox regression analysis
| Variable | p | HR | 95% CI |
|---|---|---|---|
| Univariate cox regression analysis | |||
| ECOG | 0.003 | ||
| AGE ≥ 65 | 0.02 | 0.49 | 0.26–0.92 |
| LDH baseline ≥ 300 U/L | 0.008 | 0.41 | 0.2–0.7 |
| Bortezomib-based regimens (first line) | 0.03 | 0.46 | 0.22–0.9 |
| Bortezomib-based regimens + ASCT (first line) | 0.01 | 0.38 | 0.2–0.8 |
| ASCT | 0.01 | 0.40 | 0.2–0.8 |
| ≥VGPR | 0.009 | 0.40 | 0.20–0.8 |
| Multivariate cox regression analysis | |||
| LDH baseline ≥ 300 U/L | 0.03 | 0.45 | 0.2–0.9 |
| ≥VGPR | 0.01 | 0.39 | 0.2–0.8 |
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, vgPR very good partial response, ASCT autologous stem cell transplantation, HR hazard ratio